← 홈

프로그램 비교

타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일

현재 선택: 1개 · 임상 갱신 필요 1개

프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.

프로그램 선택

API CSV21행 · 1개 프로그램
OverviewMoAPK/PDToxicologyClinicalPreclinical

표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.

항목
CGTStandard DatabasestaleApproved
Sulfonylurea (Sulfonylurea)
Royal Devon and Exeter NHS Foundat…·Neurodevelopmental Disorders
32 trials
Overview
Program
Sulfonylurea
Overview
Company
Royal Devon and Exeter NHS Foundation Trust
Overview
Modality
CGT
Overview
Target
Neurodevelopmental Disorders
Overview
Indication
Maturity-Onset Diabetes of the Young, Type 3; Maturity Onset Diabetes of the Young, Type 1
Overview
Phase
APPROVED
Overview
Status
RECRUITING
Overview
Content status
Standard Database
Overview
Data Confidence
Data Confidence · Medium
Overview
Development Signal
Development Signal · Established
Overview
Approval status
Approved (flag incomplete)
MoA
Biomarker
biomarkers
PK/PD
Species
Rat, Human
PK/PD
Animal (cat.)
Human, Rat
PK/PD
Experiment
Pharmacokinetic
Toxicology
Species
Rat, Human
Toxicology
Animal (cat.)
Human, Rat
Toxicology
Major finding
thrombocytopenia, were unacceptably high at ILX-295501 doses exceeding 1000 mg/m(2), which was d
Clinical
Safety signal
thrombocytopenia, were unacceptably high at ILX-295501 doses exceeding 1000 mg/m(2), which was d
Clinical
Program phase
APPROVED
Preclinical
Animal (cat.)
Rat